Litcius/Paper detail

Ublituximab: a new anti-CD20 agent for multiple sclerosis

Jiwon Oh, Amit Bar‐Or

2022The Lancet Neurology10 citationsDOI

Topics & Concepts

OcrelizumabOfatumumabTeriflunomideMedicineMultiple sclerosisWeb of scienceDaclizumabRituximabDermatologyInternal medicineFingolimodMonoclonal antibodyImmunologyAntibodyLymphomaMeta-analysisMultiple Sclerosis Research StudiesImmunotherapy and Immune ResponsesPeripheral Neuropathies and Disorders